The next stage in manufacturing scale up...
With the market in allogeneic cell therapy expanding, drug developers are seeking more efficient manufacturing systems to gain a competitive edge. A major challenge here is scale-up – many early manufacturing processes use adherent (“2D”) systems, which are labor-intensive and not easily scaled. Many developers resort to ‘scaling out’ by using more culture vessels, but this adds a huge footprint and can lead to variability in cell quality, especially during seeding and harvesting.
We can help you meet the challenge of scale-up with our 3D manufacturing process. Developed with our extensive experience, this flexible bioreactor setup is centered on a universal controller, which can operate various single use vessels. 3D processes can be run with our proprietary perfusion capability. We also bring extensive microcarrier know-how.
This process can deliver quality through a controlled culture environment, quantity to meet demand, consistency between batches and efficiency with reduced hands-on time. With these benefits you can gain a competitive edge in this growing market.